CorMedix Inc. (CRMD): Price and Financial Metrics


CorMedix Inc. (CRMD): $4.23

0.24 (+6.02%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CRMD to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CRMD POWR Grades

  • Sentiment is the dimension where CRMD ranks best; there it ranks ahead of 92.72% of US stocks.
  • The strongest trend for CRMD is in Growth, which has been heading up over the past 179 days.
  • CRMD ranks lowest in Momentum; there it ranks in the 1st percentile.

CRMD Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for CRMD is 0 -- better than just 7.06% of US stocks.
  • With a price/sales ratio of 1,653.92, CORMEDIX INC has a higher such ratio than 99.73% of stocks in our set.
  • As for revenue growth, note that CRMD's revenue has grown -51.59% over the past 12 months; that beats the revenue growth of merely 3.51% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to CORMEDIX INC are WISH, DMRC, NSPR, PDEX, and BFLY.
  • Visit CRMD's SEC page to see the company's official filings. To visit the company's web site, go to www.cormedix.com.

CRMD Valuation Summary

  • CRMD's price/sales ratio is 1035.8; this is 21256.7% higher than that of the median Healthcare stock.
  • CRMD's price/earnings ratio has moved up 0.1 over the prior 152 months.

Below are key valuation metrics over time for CRMD.

Stock Date P/S P/B P/E EV/EBIT
CRMD 2022-11-01 1035.8 2.1 -4.1 -2.5
CRMD 2022-10-31 1026.0 2.0 -4.1 -2.5
CRMD 2022-10-28 1059.3 2.1 -4.2 -2.6
CRMD 2022-10-27 1062.6 2.1 -4.2 -2.6
CRMD 2022-10-26 1062.6 2.1 -4.2 -2.6
CRMD 2022-10-25 1043.1 2.1 -4.1 -2.5

CRMD Growth Metrics

    Its 3 year cash and equivalents growth rate is now at 147%.
  • The 4 year net cashflow from operations growth rate now stands at 29.7%.
  • The year over year cash and equivalents growth rate now stands at -40.38%.
Over the past 33 months, CRMD's revenue has gone down $191,163.

The table below shows CRMD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 0.092103 -24.07125 -29.28374
2022-06-30 0.123374 -23.57935 -30.99939
2022-03-31 0.110312 -21.20875 -28.02748
2021-12-31 0.190936 -21.15522 -28.21023
2021-09-30 0.190254 -21.21935 -26.50618
2021-06-30 0.245186 -23.02867 -24.53757

CRMD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CRMD has a Quality Grade of F, ranking ahead of 0.4% of graded US stocks.
  • CRMD's asset turnover comes in at 0.004 -- ranking 418th of 682 Pharmaceutical Products stocks.
  • ADAP, FBRX, and IDXX are the stocks whose asset turnover ratios are most correlated with CRMD.

The table below shows CRMD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.004 0.132 -5.939
2021-03-31 0.005 0.141 -8.398
2020-12-31 0.007 0.144 -6.360
2020-09-30 0.007 0.070 -5.242
2020-06-30 0.006 -0.103 -3.741
2020-03-31 0.007 -0.006 -2.141

CRMD Price Target

For more insight on analysts targets of CRMD, see our CRMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $21.25 Average Broker Recommendation 1.5 (Moderate Buy)

CRMD Stock Price Chart Interactive Chart >

Price chart for CRMD

CRMD Price/Volume Stats

Current price $4.23 52-week high $8.02
Prev. close $3.99 52-week low $2.64
Day low $3.94 Volume 161,100
Day high $4.35 Avg. volume 343,536
50-day MA $3.18 Dividend yield N/A
200-day MA $3.94 Market Cap 174.62M

CorMedix Inc. (CRMD) Company Bio


CorMedix Inc., a commercial pharmaceutical and medical device company, intends to in-license, develop, and commercialize prophylactic and therapeutic for the prevention and treatment of infectious and inflammatory diseases. The company was founded in 2006 and is based in Bridgewater, New Jersey.


CRMD Latest News Stream


Event/Time News Detail
Loading, please wait...

CRMD Latest Social Stream


Loading social stream, please wait...

View Full CRMD Social Stream

Latest CRMD News From Around the Web

Below are the latest news stories about CORMEDIX INC that investors may wish to consider to help them evaluate CRMD as an investment opportunity.

CorMedix Third Quarter 2022 Earnings: US$0.17 loss per share (vs US$0.23 loss in 3Q 2021)

CorMedix ( NASDAQ:CRMD ) Third Quarter 2022 Results Key Financial Results Net loss: US$6.85m (loss narrowed by 20% from...

Yahoo | November 12, 2022

Analysts Are Bullish on These Healthcare Stocks: Cormedix (CRMD), TG Therapeutics (TGTX)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cormedix (CRMD – Research Report) and TG Therapeutics (TGTX – Research Report) with bullish sentiments. Cormedix (CRMD) Needham analyst Serge Belanger maintained a Buy rating on Cormedix today and set a price target of $13.00. The company's shares closed last Thursday at $3.09, close to its 52-week low of $2.65. According to TipRanks.

Howard Kim on TipRanks | November 10, 2022

JMP Securities Remains a Buy on Cormedix (CRMD)

E ratio of -3.52.

Catie Powers on TipRanks | November 10, 2022

CorMedix Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced financial results for the third quarter and nine months ended September 30, 2022 and provided an update on recent business events. Recent Corporate Highlights: Earlie

Yahoo | November 10, 2022

CorMedix Inc. Announces CMS Revision to NTAP Reimbursement of DefenCath

BERKELEY HEIGHTS, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that the Center for Medicare & Medicaid Services (CMS) has published in the Federal Register a correction to the Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals New Technology Add on Payment (NTAP) reimb

Yahoo | November 7, 2022

Read More 'CRMD' Stories Here

CRMD Price Returns

1-mo 33.02%
3-mo 13.40%
6-mo N/A
1-year -16.57%
3-year -28.43%
5-year 59.62%
YTD -7.03%
2021 -38.76%
2020 2.06%
2019 12.87%
2018 158.00%
2017 -67.32%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.731 seconds.